These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 38439728)

  • 1. SARS-CoV-2 Infection in Pemphigus Vulgaris Two Weeks after Rituximab Therapy with Total Recovery: A Case Report.
    Róbert L; Kovács A; Sárdy M; Fábián M
    Acta Dermatovenerol Croat; 2023 Dec; 31(3):156-157. PubMed ID: 38439728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab.
    Sinagra JL; Vedovelli C; Binazzi R; Salemme A; Moro F; Mazzanti C; Didona B; Di Zenzo G
    Front Immunol; 2021; 12():665522. PubMed ID: 33936104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?
    Uzuncakmak TK; Özkoca D; Askin O; Kutlubay Z
    Dermatol Ther; 2021 Jan; 34(1):e14647. PubMed ID: 33296557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia.
    Koszegi B; Stone C; Murrell DF
    Front Med (Lausanne); 2023; 10():1149742. PubMed ID: 36999066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review.
    Calabria E; Canfora F; Mascolo M; Varricchio S; Mignogna MD; Adamo D
    Pathol Res Pract; 2022 Apr; 232():153834. PubMed ID: 35278817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy improves recalcitrant Pemphigus vulgaris.
    Noormohammadpour P; Ehsani A; Mortazavi H; Daneshpazhooh M; Balighi K; Mofidi M; Gholamali F; Sadeghinia A
    EXCLI J; 2015; 14():109-16. PubMed ID: 26417354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
    Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
    Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
    Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
    N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
    Tavakolpour S; Aryanian Z; Seirafianpour F; Dodangeh M; Etesami I; Daneshpazhooh M; Balighi K; Mahmoudi H; Goodarzi A
    Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):507-518. PubMed ID: 34287098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
    Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
    Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris.
    Jafri ZA; Walia S; Ivanic MG; Wu JJ
    J Dermatolog Treat; 2022 May; 33(3):1606-1607. PubMed ID: 33375865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.
    Beyzaee AM; Rahmatpour Rokni G; Patil A; Goldust M
    Dermatol Ther; 2021 Jan; 34(1):e14405. PubMed ID: 33051960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients.
    Kasperkiewicz M; Shimanovich I; Meier M; Schumacher N; Westermann L; Kramer J; Zillikens D; Schmidt E
    Br J Dermatol; 2012 Jan; 166(1):154-60. PubMed ID: 21910700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in pemphigus.
    Hebert V; Joly P
    Immunotherapy; 2018 Jan; 10(1):27-37. PubMed ID: 29064314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases.
    Antonucci A; Negosanti M; Tabanelli M; Varotti C
    J Dermatolog Treat; 2007; 18(3):178-83. PubMed ID: 17538808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemphigus.
    Schmidt E; Kasperkiewicz M; Joly P
    Lancet; 2019 Sep; 394(10201):882-894. PubMed ID: 31498102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide].
    España Alonso A; Panizo C; Fernández S; Marquina M; Pretel M; Aguado L; Sánchez-Ibarrola A
    Actas Dermosifiliogr; 2009 Mar; 100(2):113-20. PubMed ID: 19445875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemphigus vulgaris: a case report.
    Thanmai JV; Ramlal G; Tejaswi K; Mounica IL
    Pan Afr Med J; 2022; 42():184. PubMed ID: 36212921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.